Tucidinostat

Generic Name
Tucidinostat
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C22H19FN4O2
CAS Number
1616493-44-7
Unique Ingredient Identifier
87CIC980Y0
Indication

Investigated for use/treatment in cancer/tumors (unspecified).

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Microsatellite Stabilized (MSS/pMMR) Colorectal Cancer With Liver Metastases

Phase 2
Not yet recruiting
Conditions
Colo-rectal Cancer
Interventions
Drug: Tislelizumab
Drug: Fruquintinib
Drug: Chidamide
First Posted Date
2024-01-23
Last Posted Date
2024-01-23
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
17
Registration Number
NCT06218888

A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients

First Posted Date
2023-10-17
Last Posted Date
2023-11-02
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Target Recruit Count
42
Registration Number
NCT06087419

Low-dose Chidamide Maintenance Therapy After Allo-HSCT for T-cell Acute Lymphoblastic Leukemia or T-cell Lymphomas

Phase 2
Recruiting
Conditions
T Lymphoblastic Leukemia/Lymphoma
Interventions
Drug: Chidamide
First Posted Date
2023-08-15
Last Posted Date
2023-08-15
Lead Sponsor
Zhejiang University
Target Recruit Count
44
Registration Number
NCT05991973
Locations
🇨🇳

The First Hospital of Zhejiang Medical Colleage Zhejiang University, Hangzhou, Zhejiang, China

Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer

First Posted Date
2023-08-09
Last Posted Date
2023-08-09
Lead Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Target Recruit Count
102
Registration Number
NCT05983107
Locations
🇨🇳

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

A Retrospective Clinical Study on the First-line Maintenance Treatment of PTCL With Chidamide.

Recruiting
Conditions
PTCL
First Posted Date
2023-08-01
Last Posted Date
2023-08-01
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Target Recruit Count
200
Registration Number
NCT05967949
Locations
🇨🇳

Hematological Department, People's Hospital of Jiangsu Province, Nanjing, Jiangsu, China

Chidamide Plus Azacitidine for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma

First Posted Date
2023-07-25
Last Posted Date
2023-07-25
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Target Recruit Count
37
Registration Number
NCT05958719
Locations
🇨🇳

Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China

Study of Selinexor Combined With Chidamide in Relapsed/Refractory Acute Leukemia (AML) Patients

First Posted Date
2023-07-19
Last Posted Date
2023-07-19
Lead Sponsor
The First Affiliated Hospital of Soochow University
Target Recruit Count
42
Registration Number
NCT05951855
Locations
🇨🇳

The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy

Not Applicable
Recruiting
Conditions
HR Positive HER2 Negative Advanced Breast Cancer
Interventions
Drug: Chidamide
First Posted Date
2023-06-06
Last Posted Date
2023-06-06
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
60
Registration Number
NCT05890287
Locations
🇨🇳

天津市肿瘤医院, Tianjin, China

Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)

First Posted Date
2023-04-27
Last Posted Date
2024-02-26
Lead Sponsor
Great Novel Therapeutics Biotech & Medicals Corporation
Target Recruit Count
33
Registration Number
NCT05833724
Locations
🇨🇳

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan

🇨🇳

National Taiwan University Hospital, Taipei, Taiwan

🇨🇳

Chang Gung Memorial Hospital, Kaohsiung, Kaohsiung, Taiwan

and more 2 locations

Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients

First Posted Date
2023-04-21
Last Posted Date
2023-04-21
Lead Sponsor
The First Affiliated Hospital of Soochow University
Target Recruit Count
23
Registration Number
NCT05823701
Locations
🇨🇳

the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy